Post-Menopausal Osteoporosis Market Emerging Trends, Demand, Growth by Key Players and Forecast 2030

Comments · 386 Views

In 2021, the global post-menopausal osteoporosis treatment market exhibited significant strength, and it is projected to experience a rapid Compound Annual Growth Rate (CAGR) in revenue over the forecast period.

Market Dynamics:

In 2021, the global post-menopausal osteoporosis treatment market exhibited significant strength, and it is projected to experience a rapid Compound Annual Growth Rate (CAGR) in revenue over the forecast period. The increasing prevalence of osteoporosis among menopausal women worldwide is a driving force behind the revenue growth in the post-menopausal osteoporosis treatment market. However, a shortage of qualified experts and the side effects associated with treatment options for post-menopausal osteoporosis are the key factors impeding the market's revenue growth.

Osteoporosis is characterized by low Bone Mineral Density (BMD), a multifaceted systemic skeletal condition that results in bone fragility due to the degradation of bone tissue microstructure. The World Health Organization (WHO) defines osteoporosis as having a T-score of less than or equal to 2.5, while osteopenia is defined as having a T-score between 1.0 and 2.5. The lumbar spine and femoral neck are the anatomical regions of interest for diagnosis.

Get a sample copy of the Post-Menopausal Osteoporosis Market report: https://www.reportsanddata.com/download-free-sample/5519

Factors Supporting Market Growth:

Drivers: There are numerous factors contributing to the growth of the post-menopausal osteoporosis market. It is estimated that the prevalence of osteoporosis increases from one-third among individuals aged 50 to 60 to over 50% among those over 80 years old. By 2050, an estimated 6 million people worldwide, both men and women, will have osteoporosis, with 75% residing in developing nations. The availability of FDA-approved non-estrogen treatment options such as bisphosphonates and denosumab is boosting the treatment market for post-menopausal osteoporosis. Moreover, the increasing global population of older women, including those experiencing menopause, is contributing to market growth. In the United States, there are 9.31 million women over the age of 50 who appear to be in menopause, representing 36.8% of all females. Women constitute 21.5% of the population between the ages of 50 and 64 and 15.2% of those over 65. The market is benefiting from the development of efficient and targeted treatments, as well as innovations in medication delivery, including injectable options and vitamin supplements for symptom relief in post-menopausal osteoporosis. These medical alternatives make it easier to treat post-menopausal osteoporosis locally, contributing to revenue growth.

Restraints: Several physical therapies available in the market for the treatment of post-menopausal osteoporosis are negatively affecting the treatment market. Additionally, extended estrogen use in postmenopausal women has been linked to endometrial cancer, affecting the lining of the uterus. Hormone replacement therapy is associated with various side effects, and according to Chinese menopause guidelines, it is recommended for women at risk of osteoporotic fractures who are younger than 60 years old, but not for those older than 60. The risk of side effects appears to increase with higher doses and longer durations of use, which is hindering revenue growth in the post-menopausal osteoporosis treatment market.

Opportunities: The increasing focus on research and development in pharmaceuticals for targeted treatment of post-menopausal osteoporosis is driving market growth. Currently, new non-estrogen regulatory medications are being developed for osteoporosis treatment. There is an opportunity to educate and raise awareness among the population about the disease, which can be used by scientists and innovators to develop effective medications for post-menopausal osteoporosis patients.

Geographic Market Scenario:

Largest Market Share (North America): North America is expected to hold the largest revenue share over the forecast period. This is due to the introduction of new treatment options in the region, increased healthcare expenditures, and the availability of treatment choices. Furthermore, growing awareness of the disease has contributed to revenue growth in the region.

Fastest Growing Region (Asia Pacific): Asia Pacific is expected to register a significant revenue CAGR over the forecast period. Countries like China and India are experiencing a substantial increase in the population diagnosed with post-menopausal osteoporosis. The presence of targeted drug manufacturers and the expansion of healthcare facilities in the region are key factors expected to drive revenue growth.

Key Market Trends and Innovation:

  • Since March 2022, a phase 4 comparison study has been ongoing to assess the effectiveness of two FDA-approved medications, Ramucirumab and Denosumab, in treating osteoporosis.
  • A randomized, double-blind, multicenter phase III study to compare the efficacy and safety of RGB-14-P to Prolia in women with post-menopausal osteoporosis has been ongoing since September 21, 2021.

Competitive Landscape:

Organic and Inorganic strategies adopted:

  • As of August 2022, Pre-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients with Postmenopausal Osteoporosis.
  • In April 2019, Evenity received approval from the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women at high risk of fractures.

Major Companies in the Market Include:

  • Amgen Inc.
  • Clonz Biotech
  • Eli Lilly and Company
  • Enteris BioPharma
  • Ligand Pharmaceuticals Incorporated.
  • Merck & Co., Inc.
  • Outlook Therapeutics, Inc.
  • Paras Biopharmaceuticals

What Our Report Provides and Why Our Offering Is Better: This report provides historical data, forecasts, and revenue growth at global, regional, and country levels. It offers analysis, industry trends, and consumption patterns for each region, major country, and segment from 2019 to 2030. The report includes industry analysis, competitive landscape, company financials, and impact analysis. It covers end-use outlook, distribution channels, route of administration, treatment outlook, and regional outlook.

End-use Outlook (Revenue, USD Billion; 2019-2030):

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel Outlook (Revenue, USD Billion; 2019-2030):

  • Offline
  • Online

Route of Administration Outlook (Revenue, USD Billion; 2019-2030):

  • Oral
  • Parenteral
  • Others

Treatment Outlook (Revenue, USD Billion; 2019-2030):

  • Vitamin D
  • Bisphosphonates
  • Calcitonin
  • Hormone Replacement Therapy
  • Estrogen Antagonist
  • Parathyroid Hormone
  • Combination Therapy
  • Others

Regional Outlook (Revenue, USD Billion; 2019-2030):

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Spain, Benelux, Rest of Europe)
  • Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
  • Latin America (Brazil, Rest of Latin America)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Explore Trending Reports:

Teleradiology Market-https://www.globenewswire.com/news-release/2019/12/10/1958289/0/en/Teleradiology-Market-To-Reach-USD-11-423-4-Million-By-2026-Reports-And-Data.html

Surgical Lights Market-https://www.globenewswire.com/news-release/2020/07/27/2068129/0/en/Surgical-Lights-Market-To-Reach-USD-3-17-Billion-By-2027-Reports-and-Data.html

Sterilization Equipment Market-https://www.globenewswire.com/news-release/2019/09/25/1920852/0/en/Sterilization-Equipment-Market-To-Reach-USD-13337-1-Million-By-2026-Reports-And-Data.html

Alopecia Market-https://www.globenewswire.com/news-release/2019/04/25/1809965/0/en/Alopecia-Market-To-Reach-USD-12-99-Billion-By-2026-Reports-And-Data.html

Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5519

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse Latest Blogs: https://www.reportsanddata.com/blogs

Browse Latest Press Release: https://www.reportsanddata.com/press-release

Comments